Squarepoint
FENC icon

Squarepoint’s Fennec Pharmaceuticals FENC Stock Holding History

Squarepoint’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Sell
31,132
-25,378
-45% -$207K ﹤0.01% 3725
2026
Q1 		$348K Buy
56,510
+43,401
+331% +$335K ﹤0.01% 3598
2025
Q4 		$101K Buy
+13,109
New +$108K ﹤0.01% 4037
2024
Q3 		– Sell
-17,702
Closed -$108K – 4277
2024
Q2 		$108K Sell
17,702
-15,992
-47% -$133K ﹤0.01% 3782
2024
Q1 		$375K Buy
+33,694
New +$338K ﹤0.01% 3242
2023
Q2 		– Sell
-20,393
Closed -$170K – 3690
2023
Q1 		$170K Buy
+20,393
New +$189K ﹤0.01% 2857

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Squarepoint's FENC Position: Q2 2026 in Review

Squarepoint reduced its Fennec Pharmaceuticals (FENC) stake by 45% in Q2 2026, selling an estimated $207K and leaving 31,132 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #3725.

Squarepoint first reported a position in FENC in Q1 2023 and has held it in 6 quarters since. The position peaked at $375K in Q1 2024. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Squarepoint held 31,132 shares of Fennec Pharmaceuticals worth $335K as of Q2 2026.
  • Squarepoint sold 25,378 Fennec Pharmaceuticals shares in Q2 2026, an estimated $207K.
  • Fennec Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3725 holding.
  • Squarepoint first reported a position in Fennec Pharmaceuticals in Q1 2023 and has held it in 6 quarters since.
  • Squarepoint's Fennec Pharmaceuticals position peaked at $375K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.